| INTRODUCTION
Regular blood transfusions and use of iron chelators have changed the prognosis of thalassaemia major patients increasing survival especially for subjects born from 1980 to 1995. 1 Due to the improved survival, liver diseases related to HCV infection, including hepatocellular carcinoma (HCC), emerged after cardiac diseases as the second risk factor associated with mortality in thalassaemia. 2 While in Italy, prevalence of thalassaemia picks to 11% in Sardinia, 7 the disease is highly prevalent in the Mediterranean area. 8 Currently,
in European Countries the risk of acquiring HCV by blood transfusion is 1.5-2 per 1 million donations, by contrast, the vast majority of patients who had received regular blood red cells transfusions before 1990 acquired HCV infection. 3 It is therefore not surprisingly that the presence of HCV antibodies has been reported in 85% of multi-transfused thalassaemia patients and the presence of HCV RNA in 70% of the HCV antibodies positive thalassaemia major patients. 4 Among HCV-infected thalassaemia patients the most common HCV genotype is genotype 1 (GT1).
In patients with chronic HCV infection, anti-viral therapy reduces the risk of progression to cirrhosis, liver-related complications and HCC, 5 nevertheless, patients with concomitant systemic diseases, including hemoglobinopathies, are usually excluded from registration trials on direct acting antivirals (DAA). In the past, the use of PegInterferon (Peg-IFN) and ribavirin (RBV) in thalassaemia patients with HCV infection was limited by both IFN and RBV side effects. 9 In particular, RBV was associated with increase in blood transfusion requirements and consequent iron overload. 10 All oral IFN-free regimens based on DAAs able to block different regions of the viral genome represent the current standard of care for patients with HCV infection. LDV is a direct inhibitor of the viral region coding for HCV NS5A protein; like other first generation NS5A inhibitors, LDV has a low genetic barrier. Therefore, it is used in combination with SOF. LDV/SOF combination provides the shortest, single pill, once daily administration regimen for HCV GT1/4 and it is associated with sustained virological response (SVR) rates of 95% or higher in treatment na€ ıve and of 94% in treatment experienced HCV-infected patients. 11, 12 This treatment is expected not to be limited by drug-to-drug interactions with other medications usually taken by thalassaemia patients. Given that, in Italy, the current reimbursement rules limit treatment of thalassaemia patients to fibrosis stages of F3-F4, we evaluated SOF/LDV fixed dose combination in patients with thalassaemia major extending treatment beyond this criterion. SVR and tolerability were compared with those observed after Peg-IFN/RBV treatment in an historical control group treated at our Unit.
| PATIENTS AND METHODS

| Study design and population
One hundred and twenty-four patients with thalassaemia major and HCV infection were screened. Twenty-four patients did not meet the inclusion criteria and did not start treatment. One hundred patients were prospectively treated. 
| Study endpoints
The primary efficacy endpoint of the study was the rate of SVR which was defined as HCV RNA undetectable or ≤LLOQ, 12 or 
| Statistics
Statistical analyses were performed using SPSS (IBM, Armonk NY, 
| Ethics
The study was approved by the coordinating Site Ethic Committee and by each local ethics committee after the approval of the Italian drugs Agency (AIFA). The study was conducted in accordance with the Declaration of Helsinki.
3 | RESULTS
| Study population
From 2 January to 2 September 2016, 100 patients were screened, enrolled and treated at five sites in Italy. Baseline characteristics of patients treated with SOF/LDV are reported in Table 1 . Fifty-seven patients were male, all were Caucasian and 63% were treatment na€ ıve. Liver disease assessment showed cirrhosis in 16% of cases. In patients with cirrhosis, mean Child-Pugh score for cirrhosis mortality was A6; mean model for end stage liver disease (MELD), 7.
Mean baseline HCV RNA levels were 952 000 IU/mL (39-10 000 000). GT1 accounted for the vast majority of the infections (90 patients). Of GT1 infected patients, nine had subtype 1a and three patients with contrasting subtype results were discovered by population sequencing, only after the start of treatment, to bear Characteristics of patients who experienced a relapse in Table 2 .
Both patients were noncirrhotic and na€ ıve, infected with GT1b.
Plasma samples of these patients at baseline and 4 weeks after relapse were evaluated by population sequencing.
Overall, at week 4 of treatment, 81 patients had HCV RNA undetectable, while nine patients had HCV RNA detectable but unquantifiable. All the patients had HCV RNA undetectable at week 8 of treatment and this result was maintained through the end of treatment and of follow-up in all but two cases. and 72 at week 12 on treatment (75%). Two patients had a breakthrough. Twenty-two patients discontinued treatment due to RBV or Peg-IFN intolerance and were considered nonresponders (23%).
Twenty-five had a relapse.
| Viral resistance testing
At baseline no resistance associated substitutions were detectable in any of the two patients with virological failure. After treatment Figure 1 ).
| Safety
Overall 76% of patients treated with SOF/LDV developed adverse events. The most common adverse events among patients receiving SOF/LDV were headache (34%), fatigue (41%) and nausea (43%) ( Table 3) . No serious adverse events were registered. No patients discontinued treatment because of an adverse event.
No drug-to-drug interaction with chelation therapy including deferasirox, deferiprone or deferoxamine were observed. No changes in substitutive hormonal regimens were required.
In the historical control group, 23% of patients discontinued treatment due to RBV intolerance. No serious adverse events were registered. The most common adverse events reported in at least 2% of patients population in Table 3 . Finally, in the group of patients treated with SOF/LDV, ferritin levels were also evaluated at SVR12 and the significant decline from baseline was confirmed (769.28 ng/mL vs 649.96 ng/mL, P=.001). Medicine Agency to treat chronic HCV GT1 or GT4 infection. 11, 12 In our cohort of thalassaemia major HCV GT1 or four infected patients, this combination was associated with SVR rates of 98%. Furthermore, concomitant drug use during therapy and in particular iron chelators did not show any impact on treatment completion or tolerability. SVR rates were similar to the rates observed in phase III, ION1 study even though inclusion criteria of our study allowed the inclusion of 33% previously treated patients. 11 These findings support a future recommendation of this regimen as the preferred treatment for HCV GT1 or four chronic infected thalassaemia major patients.
| DISCUSSION
Before the recent change in the label allowing in Europe the use of SOF/LDV for 12 weeks without RBV in cirrhotic patients, we demonstrated that in thalassaemia na€ ıve cirrhotic patients RBV is not required. Indeed, the study focused on patients na€ ıve with compensated cirrhosis who were treated outside the European label recommending the use of RBV in addition to LDV for 12 weeks for all the patients with cirrhosis, 19 in keeping with AASLD recommendations instead. 20 By contrast, thalassaemia patients with cirrhosis and history of previous treatment failure were treated at each site within the Italian reimbursement recommendations for 24 weeks in parallel with this study. 21 Our results support the use of SOF/LDV for 12 weeks without ribavirin in na€ ıve patients with cirrhosis as recently reported by the label. Remarkably, SVR12 rates were consistent with those reported in registration studies in subgroups of patients with compensated cirrhosis and with history of prior treatment failure. Moreover, the proportion of patients with SVR12
was similar across all different subgroups traditionally associated with lower SVR including subtype 1a.
11,12
Patients with thalassaemia major were shown to have when HCV infected a greater risk of HCC. 22 Indeed, due to the concomitant iron overload a prevalence of HCC six times higher than expected has been reported. 22, 23 Moreover, an increased progression of fibrosis can be observed in subjects with thalassaemia major and simultaneous HCV infection and iron overload, as compared with patients with iron overload or HCV alone or without HCV and iron overload. 24, 25 It is therefore extremely shown). We should anyway point out that in this study no drug concentration measurement had been planned. Therefore, adherence to treatment was evaluated only on the basis of pills count.
The regimen was safe and well tolerated. AEs and serious AEs were consistent with SVR12 rates reported in patients without thalassaemia enrolled in phase II and III studies.
When the results of IFN-free treatment were compared with those attained in patients with similar proportion of cirrhosis or mild liver disease treated in the past with Peg-IFN and RBV, our data demonstrated that Peg-IFN/RBV free therapy is not only associated as expected with significantly higher SVR but also, more importantly, with irrelevant side effects, lack of increases in the transfusion's number during treatment and consequent lack of significant ferritin levels increase.
Other regimens as the combination of elbasvir and grazoprevir recently approved by EMA have been investigated in thalassaemia patients. In the C-EDGE IBLD study, 41 patients infected with HCV GT1 or four achieved 97.6% SVR with slightly lower SVR in GT 1a than in GT1b. 27 Although these results appear promising, it should be considered that the use of protease inhibitors metabolised by CYP P450 might expose patients with thalassaemia who receive a number of concomitant medications to an increased risk of drug to drug interactions.
Potential limitations of this study may be lack of centralised laboratory and histological assessments. However, the different sites laboratories used as outcome undetectable HCV RNA rather than HCV RNA <LLQ. Moreover, in the majority of patient's liver stiffness rather than liver biopsy was used to establish severity of liver damage and predefined criteria were established on the basis of IQR and a minimum of 80% rate of valid measurements. Finally, since the end point of SVR is not subject to bias, the open label design of this study is not likely to represent a bias. Follow-up studies are planned to investigate in the long-term potential benefits associated with HCV eradication in liver or not liver-related outcomes in patients with beta thalassaemia major. According to currently available liver stiffness and ferritin results, an improvement in the overall morbidity can be expected in thalassaemia patients after Peg-IFN and RBV free successful treatment.
In conclusion, SOF/LDV FDC for 12 weeks provides simple, highly effective treatment for patients with thalassaemia major and concomitant HCV GT1 or four infections. It appears an effective and safe regimen in na€ ıve patients with cirrhosis regardless of the chelators adopted. Our results also suggest high efficacy of this combination for 12 weeks in GT2 infected patients. This regimen may represent a decisive treatment to reduce morbidity and mortality in developing countries, where both the risk of HCV infection related to blood transfusion and the prevalence of thalassaemia continue to represent a concern for larger numbers of subjects.
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